Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib

    May 2020 in “ JAAD case reports ”
    Michael Brown, Katherine Smith, Sandra Osswald
    Studysummary This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaadcasereports.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata Dermatology and therapy · 2019
    2. Janus Kinase Inhibitors in Dermatology: A Systematic Review Journal of the American Academy of Dermatology · 2017
    3. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017

    Related research 4

    1. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    2. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    3. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016